Pei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.
Pei-Ling Chen, MD, PhD
Advertisement
Articles by Pei-Ling Chen, MD, PhD
Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.
Pei-Ling Chen, MD, PhD, discusses findings from a study the multiomics of patients with transformed CTCL that she led at Moffitt Cancer Center.
Pei-Ling Chen, MD, PhD, discusses epidemiology and racial disparities in CTCL.
Pei-Ling Chen, MD, PhD, discusses the incidence of CTCL.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
5